Communiqués Merck KGaA OTC Markets

Actions

MKKGY

US5893392093

Marché Fermé - OTC Markets Autres places de cotation 21:47:17 14/06/2024			Varia. 5j.	Varia. 1 janv.
36,73 ^USD	-1,00%		-0,68%	+15,03%

11/06	Merck KGaA va construire un bâtiment de 62 millions d'euros pour ses activités dans le domaine des sciences de la vie	MT
06/06	Merck KGaA achève l'agrandissement de son centre de distribution allemand pour 180 millions d'euros	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Merck : Q1 24 Financial Statement	16/05	PU
Merck : Q1 24 Earnings Presentation	16/05	PU
Merck : Q1 24 Quarterly statement	15/05	PU
Caris Life Sciences Announces Partnership with Merck KGaA, Darmstadt, Germany to Discover Novel Cancer Targets and Accelerate First-In-Class Antibody Drug Conjugate Development	05/04	AQ
Merck's Corporate Venture M Ventures Arm Backs Nucleai to Advance Its First-in-class Spatial AI Biomarker in Active Clinical Enrollment	04/04	AQ
Merck : Prospectus - C-029771	28/03	PU
DD: Merck KGaA: Dr. Matthias Heinzel, buy	27/03	EQ
DD: Merck KGaA: Peter Guenter, buy	27/03	EQ
Merck KGaA, Darmstadt, Germany, Invests More than EUR 300 Million in New Life Science Production Site in Korea	21/03	AQ
AFR: Merck KGaA: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]	25/01	EQ
AFR: Merck KGaA: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements	25/01	EQ
Biocytogen Launches RenBiologics, a Sub-Brand Focused on Out-Licensing Fully Human Antibodies for Therapeutic Development	24/01	AQ
Inspirna Partners with Merck KGaA, Darmstadt, Germany, to Accelerate Global Development of Ompenaclid	05/01	AQ
Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	13/12	EQ
Merck KGaA: Phase III trial results for evobrutinib in relapsing multiple sclerosis did not meet primary endpoint of reducing annualized relapse rates (ARR) compared to oral teriflunomide	05/12	EQ
Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	27/11	EQ
Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	24/11	EQ
Veeva European Commercial Summit Gathers Life Sciences Industry Leading the Next Generation of Commercial Excellence	23/11	AQ
Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	22/11	EQ
Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	21/11	EQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

MERCK : Un point de départ plus bas pour une croissance future

Le 27 mai 2024 à 09:36

Merck KGaA : Une big pharma européenne au momentum porteur

Le 19 janvier 2023 à 15:25